August 2026

2026-08-31 🏢 2

Today's run surfaced two business developments: Genentech licensed DualityBio's next-gen ADC payload platform to get ahead of TOP1-inhibitor resistance, and Alnylam pushed back on AstraZeneca/Ionis's disappointing Wainua trial data as a threat to the broader ATTR-CM stabilizer-plus-silencer strategy.